An Innovative Repurposing of Mefloquine; Assessment of Its Therapeutic Efficacy in Treating Cryptosporidium Parvum Infection of Both Immunocompetent and Immunocompromized Mice

Mefloquine loaded niosomes as a promising approach for the treatment of acute and chronic toxoplasmosis

“…MQ is frequently used in malaria prophylaxis and treatment of chloroquine-resistant Plasmodium falciparum (Schlagenhauf, 2010). MQ has proved to possess excellent anti-parasitic activities, especially against apicomplexan parasites such as Babesia (Munkhjargal et al, 2012) and Cryptosporidium parvum (Aly et al, 2017). Moreover, MQ has shown activity against Schistosoma (Keiser and Utzinger, 2012), Fasciola gigantica (Shalaby et al, 2016), and Echinococcus multilocularis (Rufener et al, 2018), besides its action against some Gram-positive bacteria and multidrug-resistant Mycobacterium tuberculosis (Krieger et al, 2015).…”